vimarsana.com

Page 3 - T Dm1 News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Use of ADCs in the Second-Line Treatment of HER2+ mBC

Experts introduce the antibody-drug conjugates (ADCs) trastuzumab emtansine (T-DM1) and trastuzumab deruxtecan (T-DXd) and discuss clinical trial findings and potential use in special patient populations, such as those with brain metastases.

HER2CLIMB-02: Tucatinib and T-DM1 in HER2+ Breast Cancer

Megan Kruse, MD, discusses the HER2CLIMB-02 study and the impact it may have on the HER2+ metastatic breast cancer treatment landscape.

Ongoing Research in HER2+ Metastatic Breast Cancer

An overview of agents and treatment strategies currently being investigated in HER2+ metastatic breast cancer.

Detailed text transcripts for TV channel - KGO - 20120604:10:44:00

a possible breakthrough. this is huge news. it s a drug cocktail that seems to be as effective as chemo but without some of those awful side effects. abc s john schriffen introduces us to a woman alive because of it. reporter: this is a big step for 28-year-old bridget spencer. exercising, feeling better than ever, trying to put the last seven years behind her. just a week after graduating from college, she was diagnosed with stage 4 breast cancer. i had had 7 surgeries, 32 rounds of radiation and i had been on 14 different drugs. reporter: but the cancer grew through the chemo spreading to her liver, lung and bones. desperate, she turned to a drug trial. she had a more powerful cocktail called t-dm1. it s like a heat seeking missile with a toxic payload. travels all over the body until it meets the cancer cell and then lets off a massively toxic dose to kill off the cancer without damaging the rest of the body.

© 2025 Vimarsana

vimarsana © 2020. All Rights Reserved.